Staphylococcus aureus

Turn Therapeutics Reports GX-03 Skin Inflammation Research

Westlake Village, California, August 20, 2026 Turn Therapeutics announced new peer-reviewed research providing in-vivo evidence that GX-03 selectively reduces...

By cGxPwire Editor
August 21, 2026

Bio-Pharma

Armata Advances AP-SA02 Toward Phase III Bacteremia Trial

LOS ANGELES, July 20, 2026 Armata Pharmaceuticals, Inc. has announced significant clinical, regulatory, manufacturing, and operational progress supporting the...

By cGxPwire Editor
July 21, 2026

.Clinical

Armata Secures $2.5M DoD Funding for AP-SA02

LOS ANGELES, Calif. | June 23, 2026 Armata Pharmaceuticals has received an additional $2.5 million in non-dilutive funding from...

By cGxPwire Editor
June 24, 2026

Veterinary

Boehringer Introduces LENZELTA Vaccine for Mastitis Control

INGELHEIM, GERMANY, April 13, 2026 Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in...

By cGxPwire Editor
April 15, 2026

Bio-Pharma

Armata Announces Phase 2a Success for S. aureus Phage Therapy

Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...